Table 2 Incidence of major transplant outcome variables.

From: GVHD prophylaxis in matched related stem cell transplantation: Why post-transplant cyclophosphamide can be recommended a study by the EBMT transplant complications working party

 

rATG (CI 95%)

PTCy (CI 95%)

Non-relapse mortality

12.5% (11.4–13.6)

13.1% (10.9–15.4)

Relapse incidence

32.8% (31.2–34.4)

26.2% (23.2–29.2)

Overall survival

64.8% (63.1–66.4)

68.5% (65.2–71.6)

Progression-free survival

54.7% (53–56.4)

60.7% (57.3–64)

GVHD-free and Relapse-free survival

42.7% (41–44.4)

46.5% (43.1–49.8)

Acute GVHD-II/IV

19.5% (18.2–20.7)

21.4% (18.9–24)

Acute GVHD-III/IV

7.7% (6.9–8.6)

7.6% (6–9.3)

Chronic GVHD

28.9% (27.4–30.5)

34.4% (31.2–37.6)

Extensive chronic GVHD

12.6% (11.5–13.8)

16.1% (13.7–18.7)

  1. All outcomes except acute GVHD are given at two years. Acute GVHD is given at day +100 after alloSCT.
Back to article page